In a Joint venture of Department of Bio-technology (DBT), Indian
Council of Medical Research (ICMR) and Ministry
of Health & Family Welfare (MOH & FW), ICMR has taken a lead
for promoting “Indigenous diagnostic technologies for diagnosis of
TB and MDR/XDR–TB” developed by Indian scientists/companies.
There is a need for better kits for the detection
of TB-MDR/XDR TB under the programme. There are various indigenous
technologies developed by Indian scientists for detection of MDR/XDR
TB and these technologies are in advanced stages of development and
need support and partnerships from Government and industry to enable
commercialization. It is important to identify the best technologies
based on defined parameters and then pick them up for
commercialization without losing time.
The objective of this initiative is to learn the status of
the Indian indigenous technologies developed by the Indian
researchers and discuss the way forward so that these can be made
available/commercialized for larger use.
Under this Joint initiative, an ‘Expert
Group’ has been constituted under Chairmanship of Sec. DHR &
DG, ICMR which evaluates the potential TB diagnostic kit and till
now a total of six meetings have been held and two diagnostic tests
have been shortlisted for validation. The aim of these meetings is
to connect the companies to the Government as public private
partners between the Government, academic institutions and industry.
The important parameters for evaluating the TB diagnostic
kits are given in table1.
It is the time to push best Indian technologies
forward and Government is committed to provide financial support for
the validation of these technologies in a collaborative manner. MOH&FW
will extend full support to take these technologies forward if they
are ready, cost effective and are found to be suitable for use in
the programme as per the recommendations of the Committee. The funds
for external validation would be provided by DBT/ICMR/DHR and the
external validation would be carried out in a multicentric manner.
The scientists, companies and the researchers
working in this area are encouraged to send the details of their
diagnostic kit(s) in the given format (
) to ICMR at the
following address, if interested. The researchers and companies can
work on developing cheap, point of care test, molecular technologies
for use in programme in PHC’s, CHC level, in district microscopy
centers under RNTCP. The technology picking up maximum number of
mutations and providing result in one day and are cost effective
would be preferred.
|| Dr. Rashmi Arora, Head, Division of ECD,
Indian Council of Medical Research,
V. Ramalingaswami Bhawan, Ansari Nagar,
Phone number: 011-26588296; Fax:
Dr. Manjula Singh
Sci ‘D’/ Assistant
Division of ECD
ICMR, V. Ramalingaswami Bhawan,
Phone number: 011-26589505
and Nodal Officer Tuberculosis Programme
Medical Biotechnology Division,
Department of Biotechnology,
CGO complex, New Delhi-110003
Phone number: 011-24369611 E-mail: